(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) fell by a staggering 13.51% to $15.69 at 11:27 EST on Tuesday, after two sequential sessions in a row of losses. NASDAQ is jumping 0.42% to $13,391.73, after two sequential sessions in a row of losses. This seems, at the moment, a somewhat positive trend exchanging session today.
Viking Therapeutics’s last close was $18.14, 29.47% below its 52-week high of $25.72.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.79.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.
Yearly Top and Bottom Value
Viking Therapeutics’s stock is valued at $15.69 at 11:27 EST, way under its 52-week high of $25.72 and way higher than its 52-week low of $2.54.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be overbought (>=80).
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.84%, a negative 0.89%, and a positive 5.48%.
Viking Therapeutics’s highest amplitude of average volatility was 5.63% (last week), 3.43% (last month), and 5.48% (last quarter).
Moving Average
Viking Therapeutics’s value is way under its 50-day moving average of $21.97 and way higher than its 200-day moving average of $10.97.
More news about Viking Therapeutics (VKTX).
